Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5Other hematologic neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Gemcitabine 3sargramostim 2pertuzumab 2binimetinib 2Trastuzumab 2Specimen Handling 2Polymerase Chain Reaction 2Paclitaxel 2Nicotine 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Counseling 2Bupropion 2Azacitidine 2vandetanib 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1temsirolimus 1tanespimycin 1sapanisertib 1romidepsin 1relatlimab 1pembrolizumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1motesanib diphosphate 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Neoplasms × bintrafusp alfa protein, human × Other hematologic neoplasm × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡